Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients

UCB

Status: Completed

Conditions: Epilepsy

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00394927

N01228

Details and patient eligibility

About

The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment. Adverse effects and considerations to modify the therapy will be assessed in pediatric and adult patients with controlled as well as uncontrolled epilepsy with different seizure types

Enrollment: 1,000 estimated patients

Sex: All

Ages: 4+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male and female patients from the age of 4 years
• Confirmed diagnosis of epilepsy requiring AED treatment
• Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
• Treatment must be stable for at least 3 months prior to assessment
• Absence of other severe and/or uncontrolled symptomatic chronic illness